Sanofi: new detailed results for duvakitug
(CercleFinance.com) - Sanofi and Teva Pharmaceuticals report new detailed results from the RELIEVE UCCD Phase IIb study of duvakitug in patients suffering from moderate to severe forms of ulcerative colitis and Crohn's disease.
The new data attest to the overall efficacy and safety of duvakitug in all pre-specified subgroups and at all the different doses studied, in these two most common inflammatory bowel diseases.
These results were the subject of two oral presentations at the 20th Congress of the European Crohn's and Colitis Organisation (ECCO) in Berlin. They motivate the launch of a Phase III program scheduled to begin in H2 2025.
Copyright (c) 2025 CercleFinance.com. All rights reserved.
The new data attest to the overall efficacy and safety of duvakitug in all pre-specified subgroups and at all the different doses studied, in these two most common inflammatory bowel diseases.
These results were the subject of two oral presentations at the 20th Congress of the European Crohn's and Colitis Organisation (ECCO) in Berlin. They motivate the launch of a Phase III program scheduled to begin in H2 2025.
Copyright (c) 2025 CercleFinance.com. All rights reserved.